THE BURNHAM INSTITUTE
IN THIS ISSUE:
> Anti-obesity
> Genetic
drug inhibits prostate cancer growth
FROM RESEARCH,
research may improve heart function
> NIH-sponsored stem cell course held at Burnham
THE POWER TO CURE.
The Burnham Report SUMMER 2004
Vol. 2, No. 1
new treatments underway for prostate cancer. Potential
Prostate cancer growth can be slowed by a commonly prescribed anti-obesity drug, according to recent work by Burnham Associate Professor Jeffrey Smith and his research team. The investigators showed that the drug, orlistat (marketed by Roche as XENICAL™), inhibits prostate tumor growth in mice without any apparent side effects.
Welcome to the third issue of The Burnham Report. In this issue, you’ll read about the discovery that a commonly prescribed obesity drug may have efficacy against prostate cancer, a finding that opens the door to identifying new drugs with even more potency. You’ll learn about a growing research area at Burnham—investigations relevant to heart disease.Two of our newest faculty members round out our research team in this field. The issue of stem cell research is heating up, as Californians prepare to vote this fall on an initiative to provide state funds to support research not eligible for federal funds under current guidelines.The Burnham Institute has come forward in support of this initiative. Inside you’ll also read about our involvement in one of only five NIH-sponsored courses in human embryonic stem cell biology, held recently at Burnham and co-sponsored by Children’s Hospital Orange County. All of us at The Burnham Institute are grateful for your interest and support of our research.
“This is a big advance in the sense that
Additional screening of breast cancer
we have an approved drug—approved
and colon cancer cells revealed that
for one indication—that has another
fatty acid synthase activity is highly
target and another potential disease
active in these tumors as well, indicat-
indication, prostate cancer,” says Smith.
ing they may also be susceptible to
Tumor cells require enormous
orlistat or a similar drug. Orlistat was
amounts of energy to fuel their unbri-
originally developed to inhibit an
dled growth and division. Orlistat
enzyme that processes fats in the
works to cut off this energy supply by
digestive tract, thereby preventing
disabling an enzyme that plays a key
absorption of dietary fat.
role in metabolism, the production of
The screening method developed
energy from food. Smith and his col-
and used by Smith in this study repre-
leagues developed a chemical screen
sents a quantum leap in drug discovery.
that showed that prostate cancer cells
It allows investigators to compile
have unusually high levels of the
a comprehensive profile of a drug or
enzyme fatty acid synthase, which con-
potential drug’s activities, revealing
verts dietary carbohydrate to fat. The
unintended functions. Smith now
same screen also identified orlistat’s
plans to work on synthesis and testing
ability to block the enzyme. The results
of derivatives of orlistat to increase
were published in the March 15th edi-
the effectiveness of the drug’s action
tion of the journal Cancer Research.
toward tumors.
JOHN C. REED, M.D., PH.D.
President and CEO
Jeffrey Smith, Ph.D. Associate Professor, Cancer Center